9969 Stoklara Genel Bakış Bir biyofarmasötik şirketi olan InnoCare Pharma Limited, Çin'de kanser ve otoimmün hastalıkların tedavisi için ilaç keşfetme, geliştirme ve ticarileştirme faaliyetlerinde bulunmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
InnoCare Pharma Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti InnoCare Pharma Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$5.93 52 Haftanın En Yüksek Seviyesi HK$7.92 52 Haftanın En Düşük Seviyesi HK$4.03 Beta 1.02 1 Aylık Değişim -3.73% 3 Aylık Değişim 10.84% 1 Yıllık Değişim -7.49% 3 Yıllık Değişim -60.57% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -56.20%
Son Haberler & Güncellemeler
Third quarter 2024 earnings released: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023) Nov 12
InnoCare Pharma Limited Announces Phase II Clinical Study of Icp-488 for the Treatment of Moderate-To-Severe Plaque Psoriasis Oct 10
InnoCare Pharma Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients Oct 09
InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024 Sep 30
InnoCare Pharma Limited Announces Board and Committee Changes Sep 25
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China Sep 19 Daha fazla güncelleme görün
Third quarter 2024 earnings released: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023) Nov 12
InnoCare Pharma Limited Announces Phase II Clinical Study of Icp-488 for the Treatment of Moderate-To-Severe Plaque Psoriasis Oct 10
InnoCare Pharma Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients Oct 09
InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024 Sep 30
InnoCare Pharma Limited Announces Board and Committee Changes Sep 25
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China Sep 19
InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis Sep 10
Second quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.19 loss in 2Q 2023) Aug 21
InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S Jul 24
InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024 Jun 28
InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China Jun 20
InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis May 16
First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023) May 14 InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024
Full year 2023 earnings released: CN¥0.37 loss per share (vs CN¥0.60 loss in FY 2022) Mar 29
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib Mar 29
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China Mar 13
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023 Jan 29
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China Jan 24
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA Jan 16
New minor risk - Profitability Dec 28 InnoCare Pharma Appoints Xin Fu as Chief Financial Officer
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH Dec 11
Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022) Nov 14
New minor risk - Profitability Oct 31
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China Oct 27
Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director Oct 12
InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023. Sep 22
InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023. Sep 21
InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib Sep 14
InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology Sep 13
Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022) Sep 02
Innocare Pharma Limited Announces Board Changes Jul 15
InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.16 loss in 1Q 2022) May 10
No longer forecast to breakeven Mar 30
Full year 2022 earnings released: CN¥0.60 loss per share (vs CN¥0.047 loss in FY 2021) Mar 29
Forecast breakeven date pushed back to 2025 Feb 16
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022 Jan 30
InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium Jan 28
Now 27% undervalued Dec 28
InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong Dec 28
No longer forecast to breakeven Dec 27
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China Dec 21
InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore Nov 22
Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021) Nov 16
Less than half of directors are independent Nov 16
InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022 Nov 02
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China Oct 31 InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion. Sep 15
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China Sep 13
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China Sep 10
InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA Sep 07
InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA Sep 06
No longer forecast to breakeven Sep 01
InnoCare Pharma Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong Aug 31
InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369 Aug 24
First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.16 loss in 1H 2021) Aug 24
InnoCare Pharma Limited Provides Earnings Guidance for the Nine Months Ended 30 September 2022 Aug 23
InnoCare Pharma Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China Aug 12
Innocare Pharma Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 Aug 06
InnoCare Pharma Limited Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China Aug 02
Innocare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program Jul 22
InnoCare Pharma Limited Announces Approval of Clinical Trial of Novel Targeted Protein Degrader Icp-490 in China Jul 09
InnoCare Pharma Limited Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China Jun 22
Innocare Announces Approval to Conduct A Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China May 27
Forecast breakeven date pushed back to 2024 Apr 27
Less than half of directors are independent Apr 27
InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022 Apr 11
Innocare Pharma Limited Announces Executive Changes Apr 01 InnoCare Pharma Limited Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China Mar 28
Insider recently bought HK$18m worth of stock Mar 10
InnoCare Pharma Limited Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China Mar 03
InnoCare Pharma Limited to Report Fiscal Year 2021 Results on Mar 31, 2022 Feb 26 InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended December 31, 2021
InnoCare Pharma and Keymed Biosciences Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355 Jan 18
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355 Sep 20
Forecast to breakeven in 2021 Sep 11
Forecast to breakeven in 2021 Sep 08
Forecast to breakeven in 2021 Sep 02
InnoCare Announces Clearance by U.S. FDA of Clinical Trial of pan-TRK Inhibitor ICP-723 Aug 31
First half 2021 earnings released: CN¥0.16 loss per share (vs CN¥0.53 loss in 1H 2020) Aug 30
InnoCare Provides Update on Clinical Trial of ICP-332 Aug 16
Forecast breakeven pushed back to 2023 Aug 15
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of ITP in China Aug 11
No longer forecast to breakeven Jul 16
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China Jun 26
InnoCare Presents the Latest Clinical Data of the Bruton's Tyrosine Kinase (BTK) Inhibitor Orelabrutinib Jun 19
InnoCare Presents Latest Clinical Data of Pan-FGFR Inhibitor Gunagratinib At the 2021 ASCO Annual Meeting Jun 05
InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China May 18
Full year 2020 earnings released Apr 25 Hissedar Getirileri 9969 HK Biotechs HK Pazar 7D -3.6% -2.9% 0.8% 1Y -7.5% -6.5% 21.1%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 9969 geçen yıl % -6.5 oranında getiri sağlayan Hong Kong Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: 9969 geçen yıl % 21.1 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 9969's price volatile compared to industry and market? 9969 volatility 9969 Average Weekly Movement 8.9% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
İstikrarlı Hisse Senedi Fiyatı: 9969 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 9969 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir biyofarmasötik şirketi olan InnoCare Pharma Limited, Çin'de kanser ve otoimmün hastalıkların tedavisi için ilaç keşfetme, geliştirme ve ticarileştirme faaliyetlerinde bulunmaktadır. Şirket, relaps ve/veya refrakter (r/r) kronik lenfositik lösemi, r/r mantle hücreli lenfoma, r/r Waldenstrom makroglobulinemisi, r/r marjinal bölge lenfoması olan hastaları tedavi etmek için bir BTK inhibitörü olan Orelabrutinib'i geliştirmektedir, r/r diffüz büyük B hücreli lenfoma (DLBCL)- MCD, r/r merkezi sinir sistemi lenfoması, combo w/MIL-62, sistemik lupus eritematozus, immün trombositopeni purpura, multipl skleroz ve nöromiyelitis optika spektrum bozukluğu. Ayrıca, kolanjiyokarsinom ve baş ve boyun kanseri dahil olmak üzere solid tümör hastalarının tedavisi için Faz I/II klinik çalışmasında olan bir pan-FGFR inhibitörü olan ICP-192'yi; nörotrofik tirozin reseptör kinaz füzyon pozitif kanserleri tedavi etmek için Faz I klinik çalışmasında olan bir pan-TRK inhibitörü olan ICP-723'ü geliştirmektedir; Otoimmün hastalıkların tedavisi için Faz I klinik çalışmasında olan yeni bir tirozin kinaz 2 inhibitörü olan ICP-332; ve lenfoma tedavisi için bispesifik bir antikor olan ICP-B02.
Daha fazla göster InnoCare Pharma Limited Temel Bilgiler Özeti InnoCare Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 9969 temel i̇stati̇sti̇kler Piyasa değeri HK$12.30b Kazançlar(TTM ) -HK$399.70m Gelir(TTM ) HK$956.83m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 9969 gelir tablosu (TTM ) Gelir CN¥898.92m Gelir Maliyeti CN¥125.58m Brüt Kâr CN¥773.34m Diğer Giderler CN¥1.15b Kazançlar -CN¥375.51m
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -0.21 Brüt Marj 86.03% Net Kâr Marjı -41.77% Borç/Özkaynak Oranı 20.9%
9969 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/23 17:39 Gün Sonu Hisse Fiyatı 2024/12/23 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları InnoCare Pharma Limited 17 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Peng Zou China International Capital Corporation Limited Tan Huan Gan Citic Securities Co., Ltd. Shitong Han Citic Securities Co., Ltd.
Göster 14 daha fazla analist 
